The American Academy Of Pain Medicine

The physicians' voice in pain medicine
  • Foundation
  • Store
  • Career Center
  • Press
  • Join-Renew
Search: Go
Member Login: Login

Enter the AAPM
Members' Community

  • Member Center
  • Patient Center
  • Library
  • Advocacy
  • Practice Management
  • CME
  • Annual Meeting
  • Safe Prescribing Resources
  • PI-CME Portal

Library

Home > Library > For Pain Researchers > 2013 Poster Abstracts
  • Research in the News
  • For Pain Researchers
    • 2013 Poster Abstracts
    • 2012 Poster Abstracts
    • Research Resources
    • Research Presentations
    • Search Clinical Trials (NIH)
    • Register a Clinical Trial (NIH)
    • Medline - US National Library of Medicine
  • Clinical Guidelines and Resources
  • Pain Facts
  • Archives
  • FDA Updates, Recalls and Warnings
  • Presented at the 2013 AAPM Annual Meeting « Back

    118

    Intermediate Doses of Hydromorphone Intrathecal Pump Leading to Myoclonus

    Kevin Kohan, DO, kevinkohan@gmail.com1, Michael Danko, MD2, (1) University Of Cincinnati, West Chester, Ohio, (2) University of Cincinnati, Cincinnati, Ohio

    Case: 56 year old male with a history of chronic low back pain presented to the hospital with one week duration of tremors and confusion. The patient was being treated with intrathecal (ITP) morphine pump, which had recently been revised to hydromorphone ITP due to severe urticaria. His family indicated that he was found in bed with intermittent tremors of the upper and lower extremities over the past week, with increased shortness of breath. On physical examination, he was noted to be saturating 94% on 5 liters of oxygen and required several verbal cues to continue the interview. His strength in the upper and lower extremities was 4/5 decreased due to poor effort. He was hyper-reflexic at 3/4. Results: Neurology admitted the patient and ruled out the patient for seizure and stroke. Pain service was consulted to evaluate the patient. After further questioning, it was discovered that the patient was receiving increasing doses of the hydromorphone. His dose was recently increased from 1.5 mg/day to 3.0 mg/day. Although 20 milligram/ milliliter concentration was used to refill the reservoir, this was not programmed in the Synchromed II Scanner. Therefore, the patient was receiving 6mg/day of hydromorphone. The dosage was corrected, and the patient’s symptoms improved over a 48-hour period. Discussion: Myoclonus is a rare side effect of increasing intrathecal opioid medications that has been reported more commonly with morphine ITP. Conclusion: Pain physicians should be aware of myoclonus as a side effect of increased dosages of intrathecal opioid medications. References: 1) De Conno F, Caraceni A, Martini C Hyperalgesia and Myoclonus with high dosages of intrathecal morphine. Pain. 1991 Dec;47(3):337-9. 2) Glavina MJ, Robertshaw R. Myoclonic spasms following intrathecal morphine. Anaesthesia. 1988 May;43(5):389-90. 3) Smith HS, Deer TR, Staats PS. Intrathecal Drug Delivery. Pain Physician. 2008 Mar;11(2 Suppl):S89-S104.

    Funding: None

  • Home
  • Member Center
  • Patient Center
  • Library
  • Advocacy
  • Practice Management
  • CME
  • Annual Meeting
  • Contact Us
  • Members' Community
  • Privacy Policy
  • Sitemap
Close

Members Only Alert Message

Please login to access AAPM member only information.
Forgot your login information?

Sign Up Today!

Join AAPM today and be part of the primary organization for physicians practicing in the specialty of pain medicine and begin accessing AAPM member benefits. 

Join
Or

Log In

Please log in and you will be redirected to the requested page.

Log In